T. Ito, H. Igarashi, H. Uehara, M.J. Berna, R.T. Jensen, Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/zollinger-ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine 92, 135–181 (2013). https://doi.org/10.1097/MD.0b013e3182954af1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

P. Goudet, A. Murat, C. Binquet, C. Cardot-Bauters, A. Costa, P. Ruszniewski, P. Niccoli, F. Ménégaux, G. Chabrier, F. Borson-Chazot, A. Tabarin, P. Bouchard, B. Delemer, A. Beckers, C. Bonithon-Kopp, Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des tumeurs endocrines) cohort study among 758 patients. World J. Surg. 34, 249–255 (2010). https://doi.org/10.1007/s00268-009-0290-1.

Article  PubMed  Google Scholar 

R.V. Thakker, P.J. Newey, G.V. Walls, J. Bilezikian, H. Dralle, P.R. Ebeling, S. Melmed, A. Sakurai, F. Tonelli, M.L. Brandi, Endocrine Society, Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012). https://doi.org/10.1210/jc.2012-1230.

Article  CAS  PubMed  Google Scholar 

C.R.C. Pieterman, S. Grozinsky-Glasberg, D. O’Toole, J.R. Howe, V. Ambrosini, S.H. Belli, M. Andreassen, N. Begum, T. Denecke, A. Faggiano, M. Falconi, J. Grey, U.P. Knigge, T. Kolarova, B. Niederle, E. Nieveen van Dijkum, S. Partelli, A. Pascher, G. Rindi, P. Ruszniewski, S. Stättner, T. Vandamme, J.W. Valle, M.-P. Vullierme, S. Welin, A. Perren, D.K. Bartsch, G.K. Kaltsas, G.D. Valk, Screening and surveillance practices for multiple endocrine neoplasia type 1-related neuroendocrine tumours in European neuroendocrine tumor society centers of excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire study. J. Neuroendocrinol. 37, e13468 (2024). https://doi.org/10.1111/jne.13468.

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.J.C. van Treijen, D.-J. van Beek, R.S. van Leeuwaarde, M.R. Vriens, G.D. Valk, Diagnosing nonfunctional pancreatic NETs in MEN1: the evidence base. J. Endocr. Soc. 2, 1067–1088 (2018). https://doi.org/10.1210/js.2018-00087.

Article  CAS  PubMed  PubMed Central  Google Scholar 

I.M. Modlin, B.I. Gustafsson, S.F. Moss, M. Pavel, A.V. Tsolakis, M. Kidd, Chromogranin a–biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010). https://doi.org/10.1245/s10434-010-1006-3.

Article  PubMed  Google Scholar 

A. Pulvirenti, D. Rao, C.A. Mcintyre, M. Gonen, L.H. Tang, D.S. Klimstra, M. Fleisher, L.V. Ramanathan, D. Reidy-Lagunes, P.J. Allen, Limited role of chromogranin a as clinical biomarker for pancreatic neuroendocrine tumors. HPB 21, 612–618 (2019). https://doi.org/10.1016/j.hpb.2018.09.016.

Article  PubMed  Google Scholar 

C.-M. Tseng, T.-Y. Cheng, T.-B. Chen, Y.-W. Tien, C.-C. Chen, J.-T. Lin, H.-P. Wang, Low accuracy of chromogranin a for diagnosing early-stage pancreatic neuroendocrine tumors. Oncol. Lett. 15, 8951–8958 (2018). https://doi.org/10.3892/ol.2018.8472.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Nanno, H. Toyama, I. Matsumoto, J. Uemura, S. Asari, T. Goto, D. Lee, T. Murakami, S. Komatsu, H. Yanagimoto, M. Kido, T. Ajiki, K. Okano, Y. Takeyama, T. Fukumoto, Reappraisal of malignant risk assessment for small (≤20 mm) non-functioning pancreatic neuroendocrine tumors. Ann. Surg. Oncol. 30, 3493–3500 (2023). https://doi.org/10.1245/s10434-023-13193-0.

Article  PubMed  Google Scholar 

A.P.J. Jilesen, O.R.C. Busch, T.M. van Gulik, D.J. Gouma, E.J.M. Nieveen van Dijkum, Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors–diagnostic accuracy: NF-pNET and low tumor burden. Dig. Surg. 31, 407–414 (2014). https://doi.org/10.1159/000370007.

Article  CAS  PubMed  Google Scholar 

T. Walter, L. Chardon, X. Chopin-laly, V. Raverot, A.-G. Caffin, J.-A. Chayvialle, J.-Y. Scoazec, C. Lombard-Bohas, Is the combination of chromogranin a and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?. Eur. J. Cancer 48, 1766–1773 (2012). https://doi.org/10.1016/j.ejca.2011.11.005.

Article  CAS  PubMed  Google Scholar 

F. Panzuto, C. Severi, R. Cannizzaro, M. Falconi, S. Angeletti, A. Pasquali, V.D. Corleto, B. Annibale, A. Buonadonna, P. Pederzoli, G. Delle Fave, Utility of combined use of plasma levels of chromogranin a and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J. Endocrinol. Invest. 27, 6–11 (2004). https://doi.org/10.1007/BF03350903.

Article  CAS  PubMed  Google Scholar 

J.M. de Laat, C.R.C. Pieterman, M. Weijmans, A.R. Hermus, O.M. Dekkers, W.W. de Herder, A.N.A. van der Horst-Schrivers, M.L. Drent, P.H. Bisschop, B. Havekes, M.R. Vriens, G.D. Valk, Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J. Clin. Endocrinol. Metab. 98, 4143–4151 (2013). https://doi.org/10.1210/jc.2013-1800.

Article  CAS  PubMed  Google Scholar 

W. Qiu, I. Christakis, A. Silva, R.L. Bassett, L. Cao, Q.H. Meng, E. Gardner Grubbs, H. Zhao, J.C. Yao, J.E. Lee, N.D. Perrier, Utility of chromogranin a, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin. Endocrinol. 85, 400–407 (2016). https://doi.org/10.1111/cen.13119.

Article  CAS  Google Scholar 

S.M. Sadowski, C. Millo, C. Cottle-Delisle, R. Merkel, L.A. Yang, P. Herscovitch, K. Pacak, W.F. Simonds, S.J. Marx, E. Kebebew, Results of (68)Gallium-DOTATATE PET/CT scanning in patients with multiple endocrine neoplasia type 1. J. Am. Coll. Surg. 221, 509–517 (2015). https://doi.org/10.1016/j.jamcollsurg.2015.04.005.

Article  PubMed  PubMed Central  Google Scholar 

A. Tirosh, G.Z. Papadakis, C. Millo, S.M. Sadowski, P. Herscovitch, K. Pacak, S.J. Marx, L. Yang, P. Nockel, J. Shell, P. Green, X.M. Keutgen, D. Patel, N. Nilubol, E. Kebebew, Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-avid tumor volume measurements. Eur. J. Endocrinol. 176, 575–582 (2017). https://doi.org/10.1530/EJE-16-1079.

Article  CAS  PubMed  PubMed Central  Google Scholar 

B. Niederle, A. Selberherr, D.K. Bartsch, M.L. Brandi, G.M. Doherty, M. Falconi, P. Goudet, T.R. Halfdanarson, T. Ito, R.T. Jensen, A. Larghi, L. Lee, K. Öberg, M. Pavel, A. Perren, S.M. Sadowski, F. Tonelli, F. Triponez, G.D. Valk, D. O’Toole, D. Scott-Coombes, R.V. Thakker, G.B. Thompson, G. Treglia, B. Wiedenmann, Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome - an international consensus statement. Neuroendocrinology 111, 609–630 (2021). https://doi.org/10.1159/000511791.

Article  CAS  PubMed  Google Scholar 

Y.J. Choi, J. Roh, S. Kim, K.-A. Lee, Y. Park, Performance evaluation of the KRYPTOR compact PLUS analyzer-based B.R.A.H.M.S. CgA II KRYPTOR assay for chromogranin a measurement. Diagnostics 11, 2400 (2021). https://doi.org/10.3390/diagnostics11122400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro, H.I. Feldman, J.W. Kusek, P. Eggers, F. Van Lente, T. Greene, J. Coresh, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009). https://doi.org/10.7326/0003-4819-150-9-200905050-00006.

Article  PubMed  PubMed Central  Google Scholar 

I. Kostiainen, S. Majala, J. Schildt, H. Parviainen, S. Kauhanen, H. Seppänen, P.J. Miettinen, N. Matikainen, E.M. Ryhänen, C. Schalin-Jäntti, Pancreatic imaging in MEN1-comparison of conventional and somatostatin receptor positron emission tomography/computed tomography imaging in real-life setting. Eur. J. Endocrinol. 188, 421–429 (2023). https://doi.org/10.1093/ejendo/lvad035.

Article  CAS  PubMed  Google Scholar 

J.N. Mandrekar, Receiver operating characteristic curve in diagnostic test assessment. J. Thorac. Oncol. 5, 1315–1316 (2010). https://doi.org/10.1097/JTO.0b013e3181ec173d.

Article  PubMed  Google Scholar 

Y. Lv, X. Han, C. Zhang, Y. Fang, N. Pu, Y. Ji, D. Wang, X. Xuefeng, W. Lou, Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocr. Connect. 7, 169–178 (2018). https://doi.org/10.1530/EC-17-0276.

Article  CAS  PubMed  Google Scholar 

K.A. Mirkin, C.S. Hollenbeak, J. Wong, Impact of chromogranin a, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm. J. Surg. Res. 211, 206–214 (2017). https://doi.org/10.1016/j.jss.2016.12.033.

Article  CAS  PubMed  Google Scholar 

D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K. Oberg, B. Skogseid, Plasma chromogranin a in patients with multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 84, 2712–2717 (1999). https://doi.org/10.1210/jcem.84.8.5938.

Article  CAS  PubMed  Google Scholar 

M. Peracchi, D. Conte, C. Gebbia, C. Penati, S. Pizzinelli, M. Arosio, S. Corbetta, A. Spada, Plasma chromogranin a in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur. J. Endocrinol. 148, 39–43 (2003). https://doi.org/10.1530/eje.0.1480039.